Goldman Sachs’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Goldman Sachs’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-314	Closed	-$135K	–	6491
2021 Q3	$135K	Buy	314 +55	+21%	+$3.6K	﹤0.01%	5847
2021 Q2	$141K	Sell	259 -27	-9%	-$1.69K	﹤0.01%	5861
2021 Q1	$112K	Buy	286 +23	+9%	+$1.73K	﹤0.01%	5811
2020 Q4	$112K	Buy	263 +158	+150%	+$10.8K	﹤0.01%	5276
2020 Q3	$89K	Sell	105 -118	-53%	-$13.5K	﹤0.01%	5108
2020 Q2	$184K	Buy	223 +91	+69%	+$7.61K	﹤0.01%	4818
2020 Q1	$49K	Sell	132 -155	-54%	-$11.1K	﹤0.01%	5055
2019 Q4	$109K	Sell	287 -54	-16%	-$5.04K	﹤0.01%	5035
2019 Q3	$579K	Sell	341 -214	-39%	-$46.2K	﹤0.01%	4373
2019 Q2	$890K	Buy	+555	New	+$157K	﹤0.01%	4067

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs's KRSA Position: Q4 2021 in Review

Goldman Sachs sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2021, closing a stake of 314 shares — an estimated $135K sold.

Goldman Sachs first reported a position in KRSA in Q2 2019 and held it in 10 quarters. The position peaked at $890K in Q2 2019. 51 funds tracked by Wall St. Rank hold KRSA as of Q4 2021.

Goldman Sachs reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 314 Korsana Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $135K.
Goldman Sachs first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Goldman Sachs's Korsana Biosciences, Inc. Common Stock position peaked at $890K in Q2 2019.
51 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.